Your browser doesn't support javascript.
loading
Probiotics: insights and new opportunities for Clostridioides difficile intervention.
Pal, Rusha; Athamneh, Ahmad I M; Deshpande, Riddhi; Ramirez, Jose A R; Adu, Kayode T; Muthuirulan, Pushpanathan; Pawar, Shrikant; Biazzo, Manuele; Apidianakis, Yiorgos; Sundekilde, Ulrik Kraemer; de la Fuente-Nunez, Cesar; Martens, Mark G; Tegos, George P; Seleem, Mohamed N.
Affiliation
  • Pal R; Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
  • Athamneh AIM; Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
  • Deshpande R; Reading Hospital, Tower Health, West Reading, PA, USA.
  • Ramirez JAR; ProbioWorld Consulting Group, James Cook University, Queensland, Australia.
  • Adu KT; ProbioWorld Consulting Group, James Cook University, Queensland, Australia.
  • Muthuirulan P; Cann Group, Walter and Eliza Hall Institute, La Trobe University, Victoria, Australia.
  • Pawar S; Department of Human Evolutionary Biology, Harvard University, Cambridge, MA, USA.
  • Biazzo M; The Anlyan Center Yale Center for Genomic Analysis, Yale School of Medicine, New Haven, CT, USA.
  • Apidianakis Y; The Bioarte Ltd Laboratories at Life Science Park, San Gwann, Malta.
  • Sundekilde UK; Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus.
  • de la Fuente-Nunez C; Department of Food Science, Aarhus University, Aarhus, Denmark.
  • Martens MG; Departments of Psychiatry and Microbiology, Machine Biology Group, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Tegos GP; Departments of Bioengineering and Chemical and Biomolecular Engineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, USA.
  • Seleem MN; Penn Institute for Computational Science, University of Pennsylvania, Philadelphia, PA, USA.
Crit Rev Microbiol ; 49(3): 414-434, 2023 May.
Article in En | MEDLINE | ID: mdl-35574602
ABSTRACT
Clostridioides difficile infection (CDI) is a life-threatening disease caused by the Gram-positive, opportunistic intestinal pathogen C. difficile. Despite the availability of antimicrobial drugs to treat CDI, such as vancomycin, metronidazole, and fidaxomicin, recurrence of infection remains a significant clinical challenge. The use of live commensal microorganisms, or probiotics, is one of the most investigated non-antibiotic therapeutic options to balance gastrointestinal (GI) microbiota and subsequently tackle dysbiosis. In this review, we will discuss major commensal probiotic strains that have the potential to prevent and/or treat CDI and its recurrence, reassess the efficacy of probiotics supplementation as a CDI intervention, delve into lessons learned from probiotic modulation of the immune system, explore avenues like genome-scale metabolic network reconstructions, genome sequencing, and multi-omics to identify novel strains and understand their functionality, and discuss the current regulatory framework, challenges, and future directions.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clostridioides difficile / Clostridium Infections / Probiotics Limits: Humans Language: En Journal: Crit Rev Microbiol Journal subject: MICROBIOLOGIA Year: 2023 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clostridioides difficile / Clostridium Infections / Probiotics Limits: Humans Language: En Journal: Crit Rev Microbiol Journal subject: MICROBIOLOGIA Year: 2023 Document type: Article Affiliation country: Estados Unidos